Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 205 clinical trials
None
A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP

dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).

thrombocytopenia
dexamethasone
platelet count
  • 0 views
  • 03 Sep, 2021
  • 2 locations
None
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or

platelet count
monoclonal antibodies
thrombocytopenia
immune globulin
leukemia
  • 0 views
  • 02 Jun, 2021
  • 1 location
None
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Fostamatinib may improve thrombocytopenia in myelofibrosis patients with severe thrombocytopenia (platelet <50,000/microL) and allow them to initiate treatment with a JAK2 inhibitor

  • 0 views
  • 14 May, 2021
  • 1 location
None
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

Hematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TMA) is an understudied complication of HCT that significantly affects transplant related morbidity and mortality. The investigators hypothesize that early intervention with complement blocker eculizumab will double survival in HCT recipients with high risk TMA, as compared to historical untreated controls. An optimal …

stem cell transplantation
eculizumab
organ dysfunction syndrome
replacement therapy
renal replacement
  • 3 views
  • 24 Jun, 2021
  • 3 locations
None
Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim

Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.

eltrombopag
thrombocytopenia
avatrombopag
romiplostim
  • 0 views
  • 17 Sep, 2021
  • 8 locations
None
Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)

treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) during the COVID-19 pandemic.

thrombocytopenia
autoimmune thrombocytopenia
covid-19
platelet count
eltrombopag
  • 0 views
  • 25 Jan, 2021
  • 1 location
None
A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP

The purpose of this study is to compare the ability of eltrombopag in combination with a short course of high-dose dexamethasone to induce sustained response off treatment in patients with newly-diagnosed ITP versus 1-3 cycles of dexamethasone monotherapy. The unmet clinical need and the potential for eltrombopag when added to …

dexamethasone
platelet count
eltrombopag
  • 20 views
  • 19 Aug, 2021
  • 21 locations
None
PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

STUDY BACKGROUND AND PURPOSE: Patients with hematological malignancies (blood-related cancers) often develop thrombocytopenia (low platelet count), which can be made

myeloid leukemia
anemia
graft versus host disease
chronic myelomonocytic leukemia
myelodysplastic syndromes
  • 29 views
  • 19 May, 2021
  • 2 locations
None
Ravulizumab and COVID-19

Ultomiris (Ravulizumab), is a monoclonal antibody that specifically targets terminal complement products and is proposed for the treatment of COVID-19 induced microvasculature injury and endothelial damage leading to thrombotic microangiopathy (TMA) causing acute kidney injury (AKI). Ravulizumab is to be used for participants with a confirmed diagnosis of COVID-19 who …

  • 0 views
  • 29 Jan, 2021
  • 1 location
None
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

Background Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which …

horse anti-thymocyte globulin
blood test
white blood cells
immunosuppression
platelet count
  • 114 views
  • 18 Jul, 2021
  • 1 location